http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
권민석,최영준,사모아,박수형,신의철 대한면역학회 2018 Immune Network Vol.18 No.6
Immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-PD-L1 Abs, have shown efficacy for the treatment of various cancers. Although research has actively sought to develop new ICIs and immunomodulators, no efficient in vitro assay system is available to evaluate their functional activities. In the present study, we established a two-round MLR with human PBMCs for evaluation of the T cell-activating capacity of anti-PD-1 and other immunomodulators. We initially performed conventional MLR for this purpose. However, anti-PD-1 blocking Abs could not increase the proliferation of allo-reactive T cells in conventional MLR because PD-L1+ and PD-L2+ cells disappeared gradually during MLR. Therefore, we re-applied the same stimulator PBMCs to the allo-stimulated responder cells as a second-round MLR on day 6 when anti-PD-1 or immunomodulators were also added. In this two-round MLR, the proliferation of allo-reactive T cells was enhanced by anti-PD-1 in a dose-dependent manner or by immunomodulators, such as lenalidomide and galunisertib, a TGF-β receptor-1 inhibitor. Proliferation was further increased by the combination of immunomodulators with anti-PD-1. Here, we established a modified two-round MLR method with human PBMCs for evaluation of the functional activities of anti-PD-1 and immunomodulators.
권민석,정태성,김신,Kwon, Min-Seok,Jung, Tae-Sung,Kim, Shin 대한소아치과학회 2003 大韓小兒齒科學會誌 Vol.30 No.2
본 연구는 기존의 할로겐광(XL 3000, 3M, U.S.A.)과 비교하여 새로운 중합광원인 플라즈마광(Flipo, LOKKI, France)과 Light Emitting Diode(이하 LED, Elipar Free light, 3M, U.S.A.)광의 효율성을 평가할 목적으로 시도되었다. 이에 본 연구에서는 첫째, 일정 광도 하에서 플라즈마광과 LED광의 중합시간에 따른 중합도의 변화를 검토하여 할로겐광의 미세경도와 유사한 광조사 시간을 알아보고, 둘째, 중합반경에 따라 균일한 중합이 이루어지는지를 보기 위해 광조사 부위의 중심부와 외측 변연부에서의 중합도의 차이를 비교하였다. 2mm 두께의 복합레진 시편의 상면과 하면의 미세경도의 측정을 통해 중합도를 평가, 비교해 본 결과 다음과 같은 결론을 얻었다. 1. Z-100의 미세경도 측정치 비교에서, 대조군인 할로겐광을 40초 적용한 경우는, 플라즈마광 6-9초, LED광 40-60초를 적용한 경우와 유사하였다(P>0.05). 2. Tetric Flow의 미세경도에서는 대조군인 할로겐광을 40초 적용한 경우, 플라즈마광 9초, LED광 40-60초를 적용한 경우와 유사하였다(P>0.05). 3. Dyract AP의 경우, 할로겐광 40초를 조사한 것은, 플라즈마광 6-9초, LED광 20-40초를 적용한 경우와 유사하게 나타났다(P>0.05). 4. Fuji II LC에서는 할로겐광을 40초 적용한 경우가, 플라즈마광 9초, LED광 20-60초를 적용한 경우와 유사하게 나타났다(P>0.05). 5. Fuji II LC를 제외한 모든 시료에서 할로겐, 플라즈마, LED광 모두 시편의 중앙에서 외측으로 갈수록 미세경도는 유의하게 감소되었다(p<0.05). The purpose of this study was to compare the effect of exposure time on the polymerization of surface and 2 mm below the surface of light-cured restorative materials cured with three different light sources; conventional halogen light curing unit(XL 3000, 3M, U.S.A.), plasma arc light curing unit(Flipo, LOKKI, France) and light emitting diode(LED) light curing unit(Elipar Free light, 3M, U.S.A.) and compare the uniformity of polymerization from the center to the periphery of resin surfaces according to polymerization diameter cure with three different light sources. From the experiment, the following results were obtained. 1. In Z-100, Plasma arc light exposure time of 6 to 9 seconds and LED light exposure time of 40 to 60 seconds produced microhardness values similar to those produced with 40 second exposure to a conventional halogen light(p>0.05). 2. In Tetric Flow, Plasma arc light exposure time of 9 seconds and LED light exposure time of 40 to 60 seconds produced microhardness values similar to those produced with 40 second exposure to a conventional halogen light(p>0.05). 3. In Dyract AP, Plasma arc light exposure time of 6 to 9 seconds and LED light exposure time of 20 to 40 seconds produced microhardness values similar to those produced with 40second exposure to a conventional halogen light(p>0.05). 4. In Fuji II LC, Plasma arc light exposure time of 9 seconds and LED light exposure time of 20 to 60 seconds produced microhardness values similar to those produced with 40second exposure to a conventional halogen light(p>0.05). 5. Except Fuji II LC, microhardness was decreased from the center to the periphery in all light sources(p<0.05).
대장암 환자에서 Capecitabine과 Bevacizumab 병합요법 후 발생한 6번 뇌신경 마비 1예
권민석,허정,박송이,최창원,홍정용,문남주,황인규 중앙대학교 의과대학 의과학연구소 2015 中央醫大誌 Vol.40 No.3
We report a transient sixth nerve palsy case after administration of capecitabine and bevacizumab. A 37-year-old woman with advanced colon cancer developed diplopia due to a sixth nerve palsy, 7 weeks after receiving capecitabine and bevacizumab. Brain imaging with MRI did not show a space occupying lesion or vascular lesion that could explain her sixth nerve palsy. After stopping all chemotherapeutic drugs for 4 weeks, the diplopia resolved without special therapy. Considering her previous history of long-term exposure to 5-fluorouracil as the metabolite of capecitabine, the bevacizumab was causative drug, associated with sixth nerve palsy. This is the first reported case of bevacizumab induced sixth nerve palsy in colon cancer.